DUBLIN, May 24, 2018 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company
will host a webcast to discuss data to be presented on solriamfetol
(JZP-110) and Xyrem® (sodium oxybate) oral solution at the Annual
Meeting of the Associated Professional Sleep Societies (APSS)
in Baltimore, MD from June 3-6, 2018.
The live webcast will begin at 7:00 p.m.
EDT on June 5, 2018.
Interested parties may access the live audio webcast via the
Investors section of the Jazz Pharmaceuticals website at
http://www.jazzpharmaceuticals.com. Please connect to the
website prior to the start of the conference call to ensure
adequate time for any software downloads that may be necessary to
listen to the webcast.
Audio webcast/conference call:
U.S. dial-in
number: +1 800 239 9838
International dial-in numbers: click here
Passcode: 5629915
An audio archive of the webcast will be available for at least
one week following the presentation on the Investors section of the
company's website at http://www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc
(Nasdaq: JAZZ) is an international biopharmaceutical company
focused on improving patients' lives by identifying, developing and
commercializing meaningful products that address unmet medical
needs. The company has a diverse portfolio of products and
product candidates with a focus in the areas of sleep and
hematology/oncology. In these areas, Jazz Pharmaceuticals
markets Xyrem® (sodium oxybate) oral solution, Erwinaze®
(asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide
sodium) and Vyxeos® (daunorubicin and cytarabine) liposome for
injection in the U.S. and markets Erwinase® and Defitelio®
(defibrotide) in countries outside the U.S. For
country-specific product information, please visit
http://www.jazzpharmaceuticals.com/products. For more
information, please visit http://www.jazzpharmaceuticals.com/ and
follow us on Twitter at @JazzPharma.
Logo-
https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_Logo.jpg